Different effects of raloxifene and estrogen on interleukin-1β and interleukin-1 receptor antagonist production using in vitro and ex vivo studies

Bone

Volumn 40, Issue 1, 2007, Pages 105-110

  Rogers, A ^a   Clowes, J A ^a   Pereda, C A ^a   Eastell, R ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cytokine; Estradiol; Interleukin 1; Osteoporosis; Raloxifene

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA ANTIBODY; LIPOPOLYSACCHARIDE; RALOXIFENE;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMPLANT; IN VITRO STUDY; MEASUREMENT; OSTEOPENIA; POSTMENOPAUSE; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; BONE DISEASES, METABOLIC; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE;

EID: 33751508163     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.07.011     Document Type: Article

References (30)

1. Riggs B.L., Khosla S., and Melton III L.J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23 (2002) 279-302
2. Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Womens Health Initiative Randomized Controlled Trial. JAMA 288 (2002) 321-333
3. Bryant H.U., Glasebrook A.L., Yang N.N., and Sato M. An estrogen receptor basis for raloxifene action in bone. J. Steroid. Biochem. Mol. Biol. 69 (1999) 37-44
4. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
5. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K., et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J. Bone Miner. Res. 13 (1998) 1747-1754
6. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice. N. Engl. J. Med. 348 (2003) 618-619
7. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
8. Prestwood K.M., Gunness M., Muchmore D.B., Lu Y., Wong M., and Raisz L.G. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 85 (2000) 2197-2202
9. Reid I.R., Eastell R., Fogelman I., Adachi J.D., Rosen A., Netelenbos C., Watts N.B., Seeman E., Ciaccia A.V., and Draper M.W. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 164 (2004) 871-879
10. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
11. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11 (1996) 1043-1051
12. Gianni W., Ricci A., Gazzaniga P., Brama M., Pietropaolo M., Votano S., et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J. Clin. Endocrinol. Metab. 89 (2004) 6097-6099
13. Gowen M., Wood D.D., Ihrie E.J., McGuire M.K., and Russell R.G. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306 (1983) 378-380
14. Rogers A., and Eastell R. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J. Bone Miner. Res. 13 (1998) 1577-1586
15. Rogers A., and Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 29 (2001) 30-34
16. Phiel, Kristen L., Henderson, Ruth A., Adelman, Steve J., Elloso M., and Merle. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol. Lett. 97 (2005) 107-113
17. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., and Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54 (1998) 105-112
18. Pereda C.A., Hannon R.A., Naylor K.E., and Eastell R. The impact of subcutaneous oestradiol implant on biochemical markers of bone turnover and bone mineral density in postmenopausal women. Br. J. Obstet. Gynaecol. 109 (2002) 812-820
19. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85 (1999) 23-29
20. Khosla S., Melton III L.J., Atkinson E.J., and O'Fallon W.M. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86 (2001) 3555-3561
21. Pacifici R., Vannice J.L., Rifas L., and Kimble R.B. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy. J. Clin. Endocrinol. Metab. 77 (1993) 1135-1141
22. Pacifici R., Brown C., Puscheck E., Friedrich E., Caplan R.H., Slatopolsky E., Maggio D., et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad Sci. U. S. A. 88 (1991) 5134-5138
23. Li Z.G., Danis V.A., and Brooks P.M. Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin. Exp. Rheumatol. 11 (1993) 157-162
24. Ralston S.H., Russell R.G., and Gowen M. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 5 (1990) 983-988
25. Bashir A., Mak Y.T., Sankaralingam S., Cheung J., Mc Gowan N.W., Grigoriadis A.E., et al. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 70 (2005) 847-855
26. Kimble R.B., Vannice J.L., Bloedow D.C., Thompson R.C., Hopfer W., Kung V.T., et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 93 (1994) 1959-1967
27. Kimble R.B., Kitazawa R., Vannice J.L., and Pacifici R. Persistent bone-sparing effect of interleukin-1 receptor antagonist: a hypothesis on the role of IL-1 in ovariectomy-induced bone loss. Calcif. Tissue Int. 55 (1994) 260-265
28. Lorenzo J.A., Naprta A., Rao Y., Alander C., Glaccum M., Widmer M., et al. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139 (1998) 3022-3025
29. Kimble R.B., Matayoshi A.B., Vannice J.L., Kung V.T., Williams C., and Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology 136 (1995) 3054-3061
30. Cheung J., Mak Y.T., Papaioannou S., Evans B.A., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177 (2003) 423-433